{
  "schemaVersion": "2.0",
  "lastUpdated": "2025-01-10",
  
  "substances": [
    {
      "id": "dmt_001",
      "name": "N,N-Dimethyltryptamine (DMT)",
      "aliases": ["DMT", "Dimitri", "Businessman's Trip", "Spirit Molecule"],
      "classification": {
        "primary": "classical_serotonergic_psychedelic",
        "secondary": ["tryptamine", "atypical_psychedelic"],
        "mechanism": "5-HT2A_agonist",
        "receptorAffinity": {
          "5HT2A": "moderate_to_high",
          "5HT1A": "moderate",
          "note": "Lower 5-HT2A affinity compared to 5-MeO-DMT, considered 'atypical' by some"
        }
      },
      "naturalSources": [
        {
          "source": "Amazonian plant species",
          "traditional_use": "Shamanic rituals, ayahuasca brew",
          "regions": ["South America"]
        },
        {
          "source": "endogenous_production",
          "description": "Produced endogenously in mammalian brains",
          "status": "endogenous_neurotransmitter"
        }
      ],
      "syntheticProduction": {
        "available": true,
        "note": "Can be produced synthetically in laboratory settings"
      },
      "prevalenceData": {
        "generalPopulation": {
          "status": "relatively_low",
          "note": "Lower prevalence compared to other psychedelics",
          "citations": ["lancelotta_2020"]
        },
        "emergencyRoomVisits": {
          "note": "Deaths from DMT alone are rare",
          "citations": ["neumann_2024", "kopra_2025"]
        }
      },
      "dosing": {
        "oral": {
          "note": "Inactive without MAOI co-administration",
          "ayahuasca_daily_dose": {
            "min": 33,
            "max": 36,
            "unit": "mg",
            "context": "Total daily dose in ayahuasca brew",
            "citations": ["neumann_2024"]
          },
          "requirement": "Must be combined with MAOI for oral bioavailability"
        },
        "intravenous": {
          "research_range": {
            "min": 0.05,
            "max": 0.4,
            "unit": "mg/kg"
          },
          "common_doses": [
            {
              "dose_range": {"min": 7, "max": 20, "unit": "mg"},
              "per_kg_range": {"min": 0.1, "max": 0.28, "unit": "mg/kg"},
              "tolerability": "well-tolerated",
              "context": "Healthy volunteers"
            }
          ],
          "effects_by_dose": [
            {
              "dose": 0.05,
              "unit": "mg/kg",
              "effects": "Mostly somaesthetic effects"
            },
            {
              "dose": 0.1,
              "unit": "mg/kg",
              "effects": "Mostly somaesthetic effects"
            },
            {
              "dose": 0.2,
              "unit": "mg/kg",
              "effects": "Strong hallucinogenic effects"
            },
            {
              "dose": 0.4,
              "unit": "mg/kg",
              "effects": "Strong hallucinogenic effects"
            }
          ],
          "onset": "Almost immediate",
          "peak": {"value": 2, "unit": "minutes"},
          "duration": {"value": 20, "unit": "minutes"},
          "citations": ["strassman_1994", "engel_2024"]
        },
        "intramuscular": {
          "onset": "Slightly slower than IV",
          "intensity": "Generally less intense than IV route",
          "citations": ["barker_2022", "falchi-carvalho_2024"]
        },
        "intranasal": {
          "note": "Free-base DMT is inactive intranasally",
          "time_to_peak": {"min": 8, "max": 10, "unit": "minutes"},
          "promise": "Promising for parenteral applications",
          "citations": ["rucker_2024", "barker_2022"]
        },
        "inhalation": {
          "recreational_typical": {"min": 6, "max": 20, "unit": "mg"},
          "research_range": {"min": 5, "max": 60, "unit": "mg"},
          "onset": "Seconds to minutes",
          "note": "Most common route outside research contexts",
          "citations": ["engel_2024", "falchi-carvalho_2024"]
        },
        "minimum_research_dose": {
          "value": 1,
          "unit": "mg",
          "context": "Lowest dose identified for research settings",
          "citations": ["rucker_2023"]
        },
        "dose_response_characteristics": {
          "curve": "steep",
          "note": "Steep dose-response curve",
          "citations": ["lancelotta_2020", "engel_2024"]
        },
        "weightDependence": true,
        "notes": "Dosing often calculated per kilogram body weight in clinical settings"
      },
      "pharmacokinetics": {
        "absorption": {
          "routes": [
            "oral_with_MAOI",
            "intravenous",
            "intramuscular",
            "intranasal",
            "inhalation"
          ],
          "note": "Route significantly affects onset and duration"
        },
        "onset": {
          "inhalation": {"min": 0, "max": 2, "unit": "minutes"},
          "intravenous": {"min": 0, "max": 1, "unit": "minutes"},
          "intramuscular": {"value": 2, "max": 5, "unit": "minutes"},
          "intranasal": {"value": 8, "max": 10, "unit": "minutes"},
          "oral_with_MAOI": {"min": 30, "max": 60, "unit": "minutes"}
        },
        "peak": {
          "inhalation": {"value": 2, "unit": "minutes"},
          "intravenous": {"value": 2, "unit": "minutes"}
        },
        "duration": {
          "inhalation": {"min": 10, "max": 60, "unit": "minutes"},
          "intravenous": {"min": 10, "max": 30, "unit": "minutes"},
          "oral_with_MAOI": {"min": 240, "max": 360, "unit": "minutes"}
        },
        "metabolism": "Rapid metabolism via monoamine oxidase",
        "elimination": "renal",
        "unique_characteristics": [
          "Brief duration of action",
          "Extreme subjective intensity relative to dosage",
          "Rapid metabolism",
          "Requires MAOI for oral bioavailability"
        ]
      },
      "subjectiveEffectTimeline": {
        "acute": {
          "timeframe": "0-30 minutes",
          "predominantEffects": [
            "breakthrough_experiences",
            "extreme_alterations_spatiotemporal_perception",
            "sense_of_transportation",
            "immersion_in_alternate_dimensions",
            "entity_encounters",
            "mystical_experiences",
            "ego_death",
            "complex_dynamic_visuals",
            "heightened_emotion",
            "increased_self_awareness"
          ]
        },
        "subacute": {
          "timeframe": "Minutes to hours post-experience",
          "predominantEffects": [
            "afterglow",
            "continued_processing",
            "emotional_integration"
          ]
        },
        "longTerm": {
          "timeframe": "Days to weeks post",
          "effects": [
            "potential_reactivations",
            "flashbacks",
            "integration_challenges",
            "behavior_change_opportunities"
          ]
        }
      },
      "toleranceDevelopment": {
        "rate": "minimal",
        "crossTolerance": ["psilocybin", "LSD", "mescaline"],
        "note": "May lead to sensitization rather than tolerance with repeated use",
        "duration": "Unknown reset period",
        "citations": ["dourron_2023"]
      },
      "addictionPotential": "minimal",
      "physiologicalDependence": "none_to_minimal",
      "psychologicalDependence": "minimal",
      "therapeuticApplications": {
        "investigated_conditions": [
          "treatment_resistant_depression",
          "mood_disorders"
        ],
        "advantages": [
          "Rapid onset",
          "Short duration",
          "Reliably produces mystical experiences",
          "Cost and time-effective potential",
          "More scalable than longer-acting psychedelics"
        ],
        "status": "Under investigation",
        "citations": ["falchi-carvalho_2024", "eckernas_2022", "dourron_2023"]
      }
    }
  ],

  "riskFactors": [
    {
      "id": "rf_dmt_dosage_001",
      "name": "High Dosage and Unknown Potency",
      "category": "dosing",
      "subcategory": "dmt_specific",
      "description": "Higher doses and unknown quantities/purity of DMT",
      "severity": "high",
      "substanceInteractions": [
        {
          "substanceId": "dmt_001",
          "mechanism": "Steep dose-response curve increases risk of overwhelming experiences",
          "riskLevel": "high",
          "specificRisks": [
            "Challenging experiences",
            "Extreme psychological distress",
            "Accidental overdosing",
            "Unpredictable effects from variable purity"
          ],
          "context": "Extreme dosing may indicate reckless behavior or underlying mental health issues",
          "illicitMarketRisks": [
            "Lack of quality control",
            "Variable potency",
            "Difficulty in accurate dosing",
            "Accidental overdose"
          ],
          "citations": ["bremler_2023", "malcolm_2022", "lancelotta_2020", "engel_2024"],
          "evidenceQuality": "moderate_to_strong"
        }
      ],
      "prevalenceInTrials": "Controlled dosing in research settings",
      "clinicalSignificance": "Critical factor in recreational use adverse events",
      "monitoringRecommendations": [
        "Use pharmaceutical-grade DMT when possible",
        "Employ accurate dosing methods",
        "Start with lower doses",
        "Test substances for purity"
      ]
    },
    {
      "id": "rf_dmt_psychiatric_001",
      "name": "Psychiatric History",
      "category": "psychiatric",
      "subcategory": "dmt_specific",
      "description": "History of psychiatric illness or treatment as DMT risk factor",
      "severity": "high",
      "substanceInteractions": [
        {
          "substanceId": "dmt_001",
          "mechanism": "DMT may trigger or exacerbate underlying psychiatric conditions",
          "riskLevel": "high",
          "specificConditions": [
            {
              "condition": "schizophrenia",
              "contraindicationType": "absolute",
              "severity": "critical"
            },
            {
              "condition": "schizoaffective_disorder",
              "contraindicationType": "absolute",
              "severity": "critical"
            },
            {
              "condition": "psychotic_depression",
              "contraindicationType": "absolute",
              "severity": "critical"
            },
            {
              "condition": "mania",
              "contraindicationType": "absolute_if_active",
              "severity": "critical"
            },
            {
              "condition": "poorer_premorbid_adjustment",
              "contraindicationType": "relative",
              "severity": "moderate_to_high",
              "note": "Increases potential risk of adverse reactions"
            }
          ],
          "citations": ["sabe_2024", "white_2024"],
          "evidenceQuality": "strong"
        }
      ],
      "recommendations": [
        "Comprehensive psychiatric screening required",
        "Avoid use in active psychotic or manic states",
        "Careful consideration of family history",
        "Enhanced monitoring if proceeding with relative contraindications"
      ]
    },
    {
      "id": "rf_dmt_polydrug_001",
      "name": "DMT Polysubstance Use",
      "category": "behavioral",
      "subcategory": "substance_use",
      "description": "Concurrent use of DMT with other substances",
      "severity": "high_to_critical",
      "substanceInteractions": [
        {
          "substanceId": "dmt_001",
          "mechanism": "Unpredictable and dangerous interactions",
          "riskLevel": "high_to_critical",
          "specificCombinations": [
            {
              "substances": ["DMT", "MDMA"],
              "effect": "Fatal adverse events documented",
              "severity": "critical",
              "citations": ["malcolm_2022", "kopra_2025"]
            },
            {
              "substances": ["DMT", "5-MeO-DMT"],
              "effect": "Fatal adverse events documented",
              "severity": "critical",
              "citations": ["malcolm_2022", "kopra_2025"]
            },
            {
              "substances": ["DMT", "MAOIs"],
              "effect": "Serotonin syndrome risk",
              "severity": "critical",
              "note": "Unless part of controlled ayahuasca preparation",
              "citations": ["malcolm_2022", "dos_santos_2024"]
            },
            {
              "substances": ["DMT", "tyramine_containing_foods"],
              "effect": "Hypertension when combined with MAOIs",
              "severity": "high",
              "citations": ["dos_santos_2024"]
            },
            {
              "substances": ["DMT", "other_substances_of_abuse"],
              "effect": "Increased risk of adverse events",
              "severity": "high",
              "citations": ["white_2024", "dos_santos_2018", "morton_2023"]
            }
          ],
          "citations": ["kopra_2025", "malcolm_2022"]
        }
      ],
      "deathData": {
        "note": "Most psychedelic-related deaths involve multiple implicated drugs",
        "polydrugInvolvement": "Primary theme in psychedelic-related deaths",
        "citations": ["kopra_2025"]
      },
      "harmReductionStrategies": [
        "Avoid combining DMT with other substances",
        "Substance testing",
        "Education about dangerous interactions",
        "Medication review before use",
        "Special caution with MAOIs and SSRIs"
      ]
    },
    {
      "id": "rf_dmt_behavioral_001",
      "name": "DMT-Specific Behavioral Risks",
      "category": "behavioral",
      "subcategory": "dmt_unique",
      "description": "Unique behavioral risks associated with DMT use",
      "severity": "moderate_to_high",
      "specificRisks": [
        {
          "risk": "lack_of_awareness",
          "description": "Users may lack awareness or memory of behaviors during acute effects",
          "consequence": "Unsafe actions without realization",
          "prevalence": "Common",
          "citations": ["dourron_2023"]
        },
        {
          "risk": "odd_behaviors",
          "description": "Muscle jerking, twitching, abnormal vocalizations",
          "consequences": ["Potential injury", "Distress to observers"],
          "citations": ["dourron_2023"]
        },
        {
          "risk": "extreme_behaviors",
          "description": "Vomiting, screaming, removing clothes",
          "context": "Can occur during acute effects",
          "citations": ["dourron_2023"]
        },
        {
          "risk": "hypersexual_experiences",
          "description": "Highly sensual or hypersexual experiences, spontaneous orgasms",
          "note": "Anecdotal reports",
          "boundary_concerns": "May increase vulnerability to exploitation",
          "citations": ["dourron_2023"]
        },
        {
          "risk": "self_injurious_behavior",
          "description": "Self-harm during experience",
          "prevalence": "Rare but documented",
          "severity": "high",
          "citations": ["dourron_2023"]
        },
        {
          "risk": "physical_danger",
          "description": "Risk of physical harm due to involuntary bodily movements",
          "mitigation": "Supervision and safe environment crucial",
          "citations": ["dourron_2023"]
        }
      ],
      "reactivationsFlashbacks": {
        "description": "Re-experiencing drug effects after acute experience subsided",
        "prevalence": {
          "variableEstimates": {"min": 15, "max": 77, "unit": "percent"},
          "naturalisticSettings": {"min": 27, "max": 73, "unit": "percent"},
          "clinicalSettings": {"value": 25, "unit": "percent", "study": "treatment-resistant depression"},
          "note": "More common with DMT than typical psychedelics"
        },
        "characteristics": {
          "duration": "Brief (seconds)",
          "components": ["Visual", "Auditory", "Emotional"],
          "onset": "Can be spontaneous",
          "timing": "More frequent at night or when drifting to sleep",
          "valence": "Most positive or neutral, some negatively valanced"
        },
        "clinicalSignificance": {
          "distress": "Minority report distress prompting psychological help",
          "persistence": "Some reports of continued flashbacks months after use"
        },
        "routeAssociation": {
          "note": "May be more common after vaporized administration"
        },
        "citations": ["dourron_2023", "ortiz_bernal_2022", "ramaekers_2025"]
      },
      "recommendations": [
        "Never use DMT alone",
        "Have trained facilitator or sitter present",
        "Ensure safe physical environment",
        "Remove hazards from setting",
        "Continuous monitoring during session",
        "Education about potential behavioral effects"
      ]
    },
    {
      "id": "rf_dmt_route_001",
      "name": "Route of Administration Risks",
      "category": "pharmacological",
      "subcategory": "administration",
      "description": "Specific risks associated with different DMT administration routes",
      "severity": "variable",
      "routes": [
        {
          "route": "smoking_vaporizing",
          "risks": [
            {
              "risk": "rapid_overwhelming_onset",
              "severity": "high",
              "description": "Very fast onset and intense effects",
              "consequences": [
                "Overwhelming experience especially for inexperienced users",
                "Heightened anxiety or panic",
                "Difficulty preparing psychologically"
              ],
              "citations": ["fradkin_2024", "bodnar_2019", "james_2024", "white_2024"]
            },
            {
              "risk": "dosing_difficulty",
              "severity": "high",
              "description": "Difficult to accurately measure dose",
              "consequences": [
                "Accidental overdosing",
                "Unpredictable effects",
                "Variable potency between uses"
              ],
              "citations": ["engel_2024", "miller_2024"]
            },
            {
              "risk": "respiratory_irritation",
              "severity": "low_to_moderate",
              "description": "Harsh on airways",
              "consequences": [
                "Coughing during inhalation",
                "Mild hoarseness",
                "Airway hyperresponsiveness",
                "Not always well-tolerated"
              ],
              "citations": ["barker_2022", "falchi-carvalho_2024", "engel_2024"]
            }
          ],
          "recommendations": [
            "Use electric combustion methods over flame combustion",
            "Inhale while seated",
            "Have sitter present for immediate onset",
            "Start with lower doses"
          ]
        },
        {
          "route": "intravenous",
          "risks": [
            {
              "risk": "extremely_rapid_intense_onset",
              "severity": "high",
              "description": "Most rapid onset and intense effects of any route",
              "consequences": [
                "Very high intensity experience",
                "Shortest duration but most intense",
                "Highest risk of acute cardiovascular reactions"
              ],
              "citations": ["barker_2022", "falchi-carvalho_2024", "fradkin_2024"]
            },
            {
              "risk": "cardiovascular_stress",
              "severity": "moderate_to_high",
              "description": "Rapid increase in plasma concentration",
              "consequences": [
                "Acute cardiovascular reactions",
                "Sudden blood pressure changes",
                "Rapid heart rate increase"
              ],
              "citations": ["barker_2022"]
            }
          ],
          "recommendations": [
            "Only in controlled clinical settings",
            "Continuous cardiovascular monitoring",
            "Medical personnel present",
            "Emergency protocols in place"
          ]
        },
        {
          "route": "intramuscular",
          "risks": [
            {
              "risk": "moderately_rapid_onset",
              "severity": "moderate",
              "description": "Slightly slower than IV but still rapid",
              "consequences": [
                "Less intense than IV",
                "More controlled than IV but still powerful"
              ],
              "citations": ["barker_2022", "falchi-carvalho_2024"]
            }
          ],
          "recommendations": [
            "Clinical setting preferred",
            "Medical supervision",
            "Monitoring during and after administration"
          ]
        },
        {
          "route": "intranasal",
          "risks": [
            {
              "risk": "variable_absorption",
              "severity": "low_to_moderate",
              "description": "Free-base DMT is inactive intranasally",
              "note": "Rapid absorption with appropriate formulation",
              "citations": ["barker_2022", "rucker_2024"]
            }
          ],
          "promise": "Promising route for parenteral applications with proper formulation"
        },
        {
          "route": "oral",
          "risks": [
            {
              "risk": "requires_MAOI",
              "severity": "critical",
              "description": "Not effective without MAOI co-administration",
              "specificRisks": [
                "Serotonin syndrome when combined with MAOIs",
                "Dangerous drug interactions",
                "Hypertensive crisis with tyramine-containing foods",
                "Longer duration increases supervision needs"
              ],
              "contraindicationType": "absolute_without_proper_supervision",
              "citations": ["engel_2024", "james_2024", "dos_santos_2024", "malcolm_2022", "barker_2022"]
            }
          ],
          "recommendations": [
            "Only in controlled ayahuasca ceremony or clinical setting",
            "Dietary restrictions (tyramine-free diet)",
            "Medication review for contraindications",
            "Longer duration requires extended supervision"
          ]
        }
      ]
    },
    {
      "id": "rf_dmt_context_001",
      "name": "Lack of Proper Preparation and Guidance",
      "category": "contextual",
      "subcategory": "preparation",
      "description": "Insufficient preparation for DMT experience",
      "severity": "moderate_to_high",
      "specificRisks": [
        "Unprepared for extreme intensity and rapid onset",
        "Lack of understanding of unique DMT phenomenology",
        "Insufficient rapport with facilitator",
        "Inadequate set and setting considerations"
      ],
      "substanceInteractions": [
        {
          "substanceId": "dmt_001",
          "riskLevel": "moderate_to_high",
          "note": "Particularly problematic for first-time users given DMT's unique characteristics",
          "citations": ["white_2024", "ramaekers_2025"]
        }
      ]
    }
  ],

  "medicalConditions": [
    {
      "id": "cond_dmt_cardiovascular_001",
      "name": "Cardiovascular Conditions (DMT-Specific)",
      "category": "physiological",
      "subcategory": "cardiovascular",
      "icd10": "I00-I99",
      "description": "Unstable or severe cardiovascular disease as contraindication for DMT",
      "substanceRisks": [
        {
          "substanceId": "dmt_001",
          "contraindicationType": "absolute_if_unstable",
          "relativeIfStable": false,
          "specificRisks": [
            {
              "risk": "acute_cardiovascular_events",
              "severity": "critical",
              "mechanism": "DMT causes increases in blood pressure and heart rate"
            }
          ],
          "physiologicalEffects": {
            "bloodPressure": {
              "increase": "moderate",
              "nature": "Generally mild and transient",
              "monitoring": "Real-time cardiovascular monitoring critical"
            },
            "heartRate": {
              "increase": "moderate",
              "nature": "Generally mild and transient",
              "habituation": "Heart rate increases habituated within 15 minutes in extended DMT infusion study"
            },
            "bodyTemperature": {
              "increase": "mild"
            }
          },
          "sympathomimeticEffects": {
            "present": true,
            "note": "DMT has sympathomimetic effects requiring cardiovascular monitoring"
          },
          "citations": ["falchi-carvalho_2024", "bodnar_2019", "ramaekers_2025", "strassman_1994", "luan_2024"],
          "evidenceQuality": "moderate_to_strong"
        }
      ],
      "screening": "Cardiovascular assessment mandatory",
      "recommendations": [
        "Absolute contraindication if cardiovascular disease is unstable",
        "Real-time cardiovascular monitoring during sessions",
        "Medical personnel present",
        "Emergency protocols in place",
        "Baseline cardiovascular assessment"
      ]
    },
    {
      "id": "cond_dmt_epilepsy_001",
      "name": "Epilepsy",
      "category": "neurological",
      "icd10": "G40",
      "description": "Epilepsy as absolute contraindication for DMT",
      "substanceRisks": [
        {
          "substanceId": "dmt_001",
          "contraindicationType": "absolute",
          "specificRisks": [
            {
              "risk": "seizure_induction",
              "severity": "critical",
              "note": "Theoretical concern, basis for exclusion from trials"
            }
          ],
          "citations": ["bodnar_2019"],
          "evidenceQuality": "theoretical_strong_consensus"
        }
      ],
      "familyHistory": {
        "relevant": true,
        "contraindicationType": "relative",
        "note": "Family history of epilepsy also warrants caution"
      }
    },
    {
      "id": "cond_dmt_pregnancy_001",
      "name": "Pregnancy",
      "category": "reproductive",
      "icd10": "Z33",
      "description": "Pregnancy as absolute contraindication for DMT",
      "substanceRisks": [
        {
          "substanceId": "dmt_001",
          "contraindicationType": "absolute",
          "specificRisks": [
            {
              "risk": "abortifacient_effects",
              "severity": "critical",
              "evidence": "Animal models with higher ayahuasca doses",
              "citations": ["white_2024"]
            },
            {
              "risk": "teratogenic_effects",
              "severity": "critical",
              "evidence": "Animal models with higher ayahuasca doses",
              "citations": ["white_2024"]
            }
          ],
          "citations": ["bodnar_2019", "white_2024"],
          "evidenceQuality": "strong"
        }
      ]
    },
    {
      "id": "cond_dmt_breastfeeding_001",
      "name": "Breastfeeding",
      "category": "reproductive",
      "description": "Breastfeeding as relative contraindication for DMT",
      "substanceRisks": [
        {
          "substanceId": "dmt_001",
          "contraindicationType": "relative",
          "specificRisks": [
            {
              "risk": "unknown_transfer_to_breast_milk",
              "severity": "moderate_to_high",
              "note": "Not known whether DMT passes into breast milk or its effect on infant"
            }
          ],
          "citations": ["marazziti_2024"],
          "evidenceQuality": "insufficient_data",
          "recommendation": "Use should be avoided during breastfeeding"
        }
      ]
    },
    {
      "id": "cond_dmt_psychotic_disorders_001",
      "name": "Psychotic Disorders",
      "category": "psychiatric",
      "icd10": "F20-F29",
      "description": "Psychotic disorders as absolute contraindication for DMT",
      "subtypes": [
        {
          "type": "Schizophrenia",
          "icd10": "F20",
          "contraindicationType": "absolute",
          "riskLevel": "critical"
        },
        {
          "type": "Schizoaffective disorder",
          "icd10": "F25",
          "contraindicationType": "absolute",
          "riskLevel": "critical"
        },
        {
          "type": "Psychotic depression",
          "icd10": "F32.3/F33.3",
          "contraindicationType": "absolute",
          "riskLevel": "critical"
        }
      ],
      "substanceRisks": [
        {
          "substanceId": "dmt_001",
          "contraindicationType": "absolute",
          "specificRisks": [
            {
              "risk": "psychotic_episode_exacerbation",
              "prevalence": "Minimal risk of psychosis from DMT alone",
              "severity": "critical",
              "vulnerablePopulations": [
                "Pre-existing psychiatric vulnerabilities",
                "Family history of psychosis",
                "Concurrent substance use"
              ]
            }
          ],
          "citations": ["sabe_2024", "white_2024", "henningfield_2023", "bodnar_2019"],
          "evidenceQuality": "strong"
        }
      ],
      "familyHistory": {
        "relevant": true,
        "contraindicationType": "absolute_for_first_degree",
        "note": "First or second-degree relatives with psychosis",
        "citations": ["rosenblat_2023"]
      }
    },
    {
      "id": "cond_dmt_bipolar_001",
      "name": "Bipolar Disorder (DMT-Specific)",
      "category": "psychiatric",
      "icd10": "F31",
      "subtypes": [
        {
          "type": "Active mania or hypomania",
          "contraindicationType": "absolute",
          "riskLevel": "critical"
        },
        {
          "type": "Non-psychotic bipolar disorder (stable)",
          "contraindicationType": "relative",
          "riskLevel": "moderate_to_high",
          "note": "Cautious approach warranted; documented evidence of switch to mania with psilocybin"
        }
      ],
      "substanceRisks": [
        {
          "substanceId": "dmt_001",
          "contraindicationType": "absolute_if_active",
          "relativeIfStable": true,
          "specificRisks": [
            {
              "risk": "manic_episode_induction",
              "severity": "high",
              "note": "Risk extrapolated from other psychedelics; similar risk may exist with DMT"
            }
          ],
          "citations": ["morton_2023", "bodnar_2019"],
          "evidenceQuality": "moderate_extrapolated"
        }
      ],
      "familyHistory": {
        "relevant": true,
        "contraindicationType": "absolute_for_first_degree",
        "riskMultiplier": "elevated"
      }
    },
    {
      "id": "cond_dmt_anxiety_disorders_001",
      "name": "Anxiety Disorders",
      "category": "psychiatric",
      "icd10": "F40-F48",
      "description": "Pre-existing anxiety disorders as relative contraindication",
      "substanceRisks": [
        {
          "substanceId": "dmt_001",
          "contraindicationType": "relative",
          "specificRisks": [
            {
              "risk": "transient_anxiety_exacerbation",
              "prevalence": "Common, especially prior to administration and during onset",
              "severity": "moderate",
              "note": "While DMT is being investigated for reducing anxiety, it may cause transient anxiety"
            }
          ],
          "citations": ["ramaekers_2025", "white_2024"],
          "evidenceQuality": "moderate"
        }
      ],
      "recommendations": [
        "Careful risk-benefit assessment",
        "Enhanced preparation",
        "Anxiety management techniques training",
        "Close monitoring during session"
      ]
    },
    {
      "id": "cond_dmt_organic_cerebral_001",
      "name": "Organic-Toxic Cerebral Disorder",
      "category": "neurological",
      "description": "Organic-toxic cerebral disorder as absolute contraindication",
      "substanceRisks": [
        {
          "substanceId": "dmt_001",
          "contraindicationType": "absolute",
          "citations": ["bodnar_2019"],
          "evidenceQuality": "strong_consensus"
        }
      ]
    },
    {
      "id": "cond_dmt_maoi_use_001",
      "name": "Concomitant MAOI Use",
      "category": "pharmacological",
      "description": "Use of MAOIs as contraindication unless in controlled protocol",
      "substanceRisks": [
        {
          "substanceId": "dmt_001",
          "contraindicationType": "absolute_unless_controlled",
          "specificRisks": [
            {
              "risk": "serotonin_syndrome",
              "severity": "critical",
              "mechanism": "Excessive serotonin accumulation",
              "exception": "MAOIs are part of controlled ayahuasca preparation"
            }
          ],
          "citations": ["dos_santos_2024", "malcolm_2022", "barker_2022"],
          "evidenceQuality": "strong"
        }
      ],
      "medications": [
        "Many antidepressants (MAOIs)",
        "Certain Parkinson's medications",
        "Other medications with MAOI activity"
      ],
      "recommendations": [
        "Comprehensive medication review required",
        "Absolute contraindication unless part of controlled ayahuasca protocol",
        "If ayahuasca context: experienced supervision, dietary restrictions",
        "Clear protocols for MAOI washout period if transitioning"
      ]
    },
    {
      "id": "cond_dmt_unstable_medical_001",
      "name": "Unstable Medical Conditions",
      "category": "physiological",
      "description": "Various unstable medical conditions as relative contraindications",
      "substanceRisks": [
        {
          "substanceId": "dmt_001",
          "contraindicationType": "relative",
          "conditions": [
            "Uncontrolled respiratory issues",
            "Severe liver impairment",
            "Severe kidney impairment",
            "Uncontrolled diabetes",
            "Other unstable systemic conditions"
          ],
          "citations": ["marazziti_2024"],
          "evidenceQuality": "moderate_consensus"
        }
      ],
      "recommendations": [
        "Comprehensive medical evaluation",
        "Risk-benefit assessment",
        "Medical monitoring if proceeding",
        "Stabilization of condition preferred before use"
      ]
    }
  ],

  "adverseEvents": [
    {
      "id": "ae_dmt_anxiety_001",
      "name": "Acute Anxiety (DMT-Specific)",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "description": "Transient anxiety during DMT experience",
      "temporalPattern": {
        "onset": "Prior to administration and during onset of effects",
        "duration": "Typically resolves as experience progresses",
        "peak": "First 5-10 minutes of experience"
      },
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "prevalence": {
            "description": "Frequently reported",
            "timing": "Particularly prior to administration and during onset",
            "context": "More common in first 10-15 minutes"
          },
          "extendedInfusion": {
            "finding": "Anxiety ratings remained low during extended DMT experiences",
            "citation": "luan_2024"
          },
          "management": {
            "primary": "reassurance_and_grounding",
            "effectiveness": "Usually sufficient",
            "techniques": [
              "Verbal reassurance",
              "Breathing guidance",
              "Calm presence of facilitator"
            ]
          },
          "citations": ["white_2024", "ramaekers_2025", "luan_2024"]
        }
      ],
      "riskFactors": [
        "First-time use",
        "High dose",
        "Rapid onset",
        "Lack of preparation",
        "History of anxiety disorders"
      ],
      "clinicalSignificance": "Usually transient; rarely requires pharmacological intervention"
    },
    {
      "id": "ae_dmt_altered_perceptions_001",
      "name": "Altered Perceptions and Hallucinations",
      "category": "perceptual",
      "timeframe": "acute",
      "severity": "moderate_to_high_intensity",
      "description": "Visual and sensory alterations during DMT experience",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "manifestations": [
            {
              "type": "visual_illusions",
              "description": "Distortions of visual perception",
              "prevalence": "Very common"
            },
            {
              "type": "hallucinations",
              "description": "Complex visual hallucinations, entity encounters",
              "prevalence": "Very common",
              "uniqueness": "Particularly characteristic of DMT"
            },
            {
              "type": "body_image_distortion",
              "description": "Altered sense of body and physical boundaries",
              "prevalence": "Common"
            },
            {
              "type": "breakthrough_experiences",
              "description": "Sense of transportation to alternate dimensions",
              "prevalence": "Common at higher doses"
            },
            {
              "type": "entity_encounters",
              "description": "Perception of sentient presences or beings",
              "prevalence": "Common",
              "uniqueness": "Particularly characteristic of DMT"
            },
            {
              "type": "white_out",
              "description": "Complete visual whiteness, loss of normal perception",
              "prevalence": "Less common",
              "severity": "High intensity"
            }
          ],
          "citations": ["falchi-carvalho_2024", "barker_2022", "dourron_2023", "luan_2024", "fradkin_2024"],
          "evidenceQuality": "strong"
        }
      ],
      "clinicalSignificance": "Expected effects; part of therapeutic/experiential process",
      "management": [
        "Preparation about what to expect",
        "Safe, supervised environment",
        "Reassurance during experience",
        "Integration support after"
      ]
    },
    {
      "id": "ae_dmt_behavioral_changes_001",
      "name": "Odd Behavioral Changes",
      "category": "behavioral",
      "timeframe": "acute",
      "severity": "moderate",
      "description": "Unusual behaviors during DMT experience",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "manifestations": [
            {
              "behavior": "abnormal_vocalizations",
              "prevalence": "Common",
              "examples": ["Unusual sounds", "Vocalization without words"]
            },
            {
              "behavior": "screaming",
              "prevalence": "Less common",
              "severity": "Moderate"
            },
            {
              "behavior": "removing_clothes",
              "prevalence": "Uncommon",
              "severity": "Moderate",
              "risk": "Vulnerability, exposure"
            },
            {
              "behavior": "vomiting",
              "prevalence": "More common with oral ayahuasca",
              "context": "Particularly with MAOI combination"
            },
            {
              "behavior": "spontaneous_orgasms",
              "prevalence": "Rare",
              "context": "Anecdotal reports of hypersexual experiences",
              "risk": "Vulnerability to exploitation"
            },
            {
              "behavior": "self_injurious_behavior",
              "prevalence": "Rare",
              "severity": "High",
              "risk": "Physical harm"
            }
          ],
          "lossOfControl": {
            "description": "Users may lack awareness or memory of behaviors",
            "implications": "Unable to regulate actions during acute effects",
            "safety": "Requires close supervision"
          },
          "citations": ["dourron_2023"],
          "evidenceQuality": "moderate"
        }
      ],
      "riskFactors": [
        "High doses",
        "Lack of supervision",
        "Unsafe environment",
        "Polysubstance use"
      ],
      "prevention": [
        "Continuous supervision",
        "Safe physical environment",
        "Removal of hazards",
        "Clear boundaries communicated beforehand"
      ],
      "clinicalSignificance": "Generally transient but requires active management"
    },
    {
      "id": "ae_dmt_paranoia_001",
      "name": "Paranoia",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "description": "Brief paranoid thoughts during DMT session",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "prevalence": {
            "value": 10,
            "unit": "percent",
            "comparison": "less_than",
            "description": "Affects fewer than 10% of patients",
            "duration": "Brief"
          },
          "citations": ["sabe_2024"],
          "evidenceQuality": "moderate"
        }
      ],
      "management": [
        "Reassurance",
        "Grounding techniques",
        "Calm environment"
      ]
    },
    {
      "id": "ae_dmt_derealization_001",
      "name": "Derealization",
      "category": "psychological",
      "timeframe": "acute_and_potentially_extended",
      "severity": "moderate",
      "description": "Loss of connection with reality during and potentially after DMT use",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "acute": {
            "prevalence": "Common during acute experience",
            "nature": "Expected part of psychedelic state"
          },
          "extended": {
            "prevalence": "Some users report long-term feeling",
            "context": "Among those with negative experiences",
            "citations": ["bremler_2023"]
          }
        }
      ],
      "riskFactors": [
        "Challenging experiences",
        "Lack of integration support",
        "Pre-existing dissociative tendencies"
      ],
      "management": [
        "Psychoeducation about transient nature",
        "Integration therapy",
        "Grounding practices"
      ]
    },
    {
      "id": "ae_dmt_cardiovascular_001",
      "name": "Cardiovascular Effects",
      "category": "physiological",
      "subcategory": "cardiovascular",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "description": "Transient increases in heart rate and blood pressure",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "effects": {
            "heartRate": {
              "change": "increase",
              "magnitude": "moderate",
              "nature": "Generally mild and transient",
              "habituation": "Habituated within 15 minutes in extended infusion study",
              "citations": ["luan_2024"]
            },
            "bloodPressure": {
              "change": "increase",
              "magnitude": "moderate",
              "nature": "Generally mild and transient"
            },
            "bradycardia": {
              "prevalence": "Rare",
              "type": "Asymptomatic",
              "citation": "white_2024"
            }
          },
          "monitoring": {
            "requirement": "Real-time cardiovascular monitoring critical",
            "reason": "DMT's sympathomimetic effects"
          },
          "citations": ["ramaekers_2025", "strassman_1994", "falchi-carvalho_2024", "white_2024"],
          "evidenceQuality": "strong"
        }
      ],
      "riskFactors": [
        "Pre-existing cardiovascular disease",
        "High doses",
        "Rapid IV administration"
      ],
      "clinicalSignificance": "Usually benign in healthy individuals; concerning in those with cardiovascular disease",
      "management": [
        "Pre-screening for cardiovascular conditions",
        "Continuous monitoring during session",
        "Medical personnel availability",
        "Emergency protocols"
      ]
    },
    {
      "id": "ae_dmt_headache_001",
      "name": "Headache",
      "category": "physiological",
      "subcategory": "neurological",
      "timeframe": "acute_and_postacute",
      "severity": "mild",
      "description": "Transient headaches during and after DMT",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "timing": [
            "During onset of effects",
            "After resolution of effects"
          ],
          "nature": "Transient",
          "prevalence": "Sometimes reported",
          "citations": ["white_2024", "rucker_2023"]
        }
      ],
      "management": [
        "Usually self-limiting",
        "Standard analgesics if needed",
        "Hydration"
      ]
    },
    {
      "id": "ae_dmt_nausea_vomiting_001",
      "name": "Nausea and Vomiting",
      "category": "physiological",
      "subcategory": "gastrointestinal",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "description": "Gastrointestinal distress during DMT experience",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "prevalence": {
            "description": "Commonly reported adverse effect",
            "route_specific": "Particularly with oral ayahuasca consumption"
          },
          "citations": ["white_2024", "rucker_2023"]
        }
      ],
      "routeSpecific": {
        "oral_ayahuasca": {
          "prevalence": "Very common",
          "cultural_context": "Sometimes considered purgative/cleansing in traditional contexts"
        },
        "other_routes": {
          "prevalence": "Less common but can occur"
        }
      },
      "management": [
        "Antiemetics if severe",
        "Comfortable positioning",
        "Preparation for possibility",
        "Bucket/basin available"
      ]
    },
    {
      "id": "ae_dmt_neuromuscular_001",
      "name": "Neuromuscular Effects",
      "category": "physiological",
      "subcategory": "neuromuscular",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "description": "Muscle-related effects during DMT",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "manifestations": [
            {
              "effect": "tremors",
              "prevalence": "Common"
            },
            {
              "effect": "muscle_fasciculation",
              "prevalence": "Common"
            },
            {
              "effect": "muscle_jerking",
              "prevalence": "Common"
            },
            {
              "effect": "twitching",
              "prevalence": "Common"
            },
            {
              "effect": "fainting",
              "prevalence": "Rare"
            },
            {
              "effect": "seizures",
              "prevalence": "Rare",
              "severity": "High"
            }
          ],
          "citations": ["falchi-carvalho_2024", "dourron_2023", "white_2024"]
        }
      ],
      "riskFactors": [
        "Epilepsy history",
        "High doses"
      ],
      "clinicalSignificance": "Usually benign; severe reactions rare",
      "management": [
        "Safe environment free of hazards",
        "Soft surfaces",
        "Supervision",
        "Medical attention if seizures occur"
      ]
    },
    {
      "id": "ae_dmt_respiratory_001",
      "name": "Respiratory Irritation",
      "category": "physiological",
      "subcategory": "respiratory",
      "timeframe": "acute",
      "severity": "mild",
      "description": "Airway irritation from inhaled DMT",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "route": "inhalation",
          "manifestations": [
            {
              "effect": "coughing",
              "timing": "During inhalation"
            },
            {
              "effect": "hoarseness",
              "severity": "Mild",
              "duration": "Transient"
            },
            {
              "effect": "airway_hyperresponsiveness",
              "prevalence": "Less common"
            }
          ],
          "note": "Respiratory effects less frequently reported overall",
          "citations": ["falchi-carvalho_2024", "white_2024"]
        }
      ],
      "prevention": [
        "Use vaporizers rather than smoking if possible",
        "Proper inhalation technique",
        "Electric combustion over flame combustion"
      ]
    },
    {
      "id": "ae_dmt_temperature_001",
      "name": "Temperature Regulation Issues",
      "category": "physiological",
      "subcategory": "thermoregulation",
      "timeframe": "acute",
      "severity": "mild",
      "description": "Altered temperature perception and regulation",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "manifestations": [
            {
              "effect": "feeling_cold",
              "note": "May occur even without objective temperature change"
            },
            {
              "effect": "elevated_body_temperature",
              "prevalence": "Can occur"
            }
          ],
          "citations": ["falchi-carvalho_2024", "strassman_1994"]
        }
      ],
      "management": [
        "Comfortable ambient temperature",
        "Blankets available",
        "Monitoring of actual body temperature if concerns"
      ]
    },
    {
      "id": "ae_dmt_other_physical_001",
      "name": "Other Acute Physical Effects",
      "category": "physiological",
      "timeframe": "acute",
      "severity": "mild",
      "description": "Additional physical effects during DMT",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "effects": [
            {
              "effect": "pupil_dilation",
              "prevalence": "Common"
            },
            {
              "effect": "increased_sweating",
              "prevalence": "Common"
            }
          ],
          "citations": ["strassman_1994", "papaseit_2018"]
        }
      ]
    },
    {
      "id": "ae_dmt_flashbacks_001",
      "name": "Flashbacks and Reactivations",
      "category": "perceptual",
      "timeframe": "subacute_to_long_term",
      "severity": "variable",
      "description": "Re-experiencing DMT effects after acute experience has ended",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "prevalence": {
            "variableEstimates": {"min": 15, "max": 77, "unit": "percent"},
            "naturalisticSettings": {"min": 27, "max": 73, "unit": "percent"},
            "clinicalSettings": {"value": 25, "unit": "percent"},
            "note": "Notable concern; more frequent with DMT than typical psychedelics"
          },
          "characteristics": {
            "duration": "Brief (on the order of seconds)",
            "components": ["Visual", "Auditory", "Emotional"],
            "spontaneity": "Can be spontaneous",
            "timing": "More frequent at night or when drifting to sleep"
          },
          "valence": {
            "most": "Positive or neutral",
            "some": "Negatively valanced",
            "distressing": "Minority report distress prompting psychological help"
          },
          "persistence": {
            "some": "Reports of continued flashbacks months after initial use"
          },
          "routeAssociation": {
            "note": "May occur more frequently with vaporized administration"
          },
          "citations": ["ramaekers_2025", "ortiz_bernal_2022", "dourron_2023", "ona_2018", "pflieger_2005"],
          "evidenceQuality": "moderate"
        }
      ],
      "differentialDiagnosis": [
        "HPPD (though less common with DMT than LSD)",
        "Anxiety-related intrusive imagery",
        "Sleep-related phenomena"
      ],
      "clinicalSignificance": "Usually benign; small minority experience distress",
      "management": [
        "Reassurance about transient nature",
        "Integration support",
        "Psychological support if distressing",
        "Rarely requires pharmacological intervention"
      ]
    },
    {
      "id": "ae_dmt_psychotic_symptoms_001",
      "name": "Psychotic Symptoms",
      "category": "psychological",
      "timeframe": "long_term",
      "severity": "moderate_to_severe",
      "description": "Prolonged psychotic symptoms following DMT use",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "prevalence": {
            "general": "Risk minimal with DMT alone",
            "vulnerable": "Primarily in individuals with pre-existing vulnerabilities"
          },
          "riskFactors": [
            "Pre-existing psychiatric vulnerabilities",
            "Family history of psychosis",
            "Concurrent use with other substances"
          ],
          "citations": ["sabe_2024", "white_2024"],
          "evidenceQuality": "moderate"
        }
      ],
      "vulnerablePopulations": [
        "Personal history of psychosis",
        "Family history of schizophrenia or psychotic disorders",
        "Active mental health symptoms",
        "Polysubstance users"
      ],
      "clinicalSignificance": "Rare but serious; requires psychiatric intervention",
      "prevention": [
        "Thorough screening",
        "Exclusion of high-risk individuals",
        "Controlled setting",
        "Professional supervision"
      ],
      "management": [
        "Psychiatric evaluation",
        "Antipsychotic medication if needed",
        "Ongoing psychiatric care",
        "Support for family/caregivers"
      ]
    },
    {
      "id": "ae_dmt_anxiety_depression_longterm_001",
      "name": "Prolonged Anxiety and Depression",
      "category": "psychological",
      "timeframe": "long_term",
      "severity": "moderate",
      "description": "Persistent anxiety or depression following DMT use",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "prevalence": {
            "description": "Some users report as long-term side effects"
          },
          "citations": ["ona_2018"]
        }
      ],
      "riskFactors": [
        "Pre-existing anxiety or depression",
        "Challenging experiences",
        "Lack of integration support",
        "Trauma history"
      ],
      "management": [
        "Psychotherapy",
        "Integration support",
        "Psychiatric evaluation",
        "May require pharmacological treatment"
      ]
    },
    {
      "id": "ae_dmt_cognitive_001",
      "name": "Cognitive Effects",
      "category": "cognitive",
      "timeframe": "long_term",
      "severity": "unclear",
      "description": "Potential long-term cognitive impacts",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "evidence": {
            "current": "No evidence of long-term cognitive deficits from DMT use",
            "citations": ["white_2024"]
          }
        }
      ],
      "note": "Current evidence suggests no long-term cognitive impairment"
    },
    {
      "id": "ae_dmt_dependence_001",
      "name": "Dependence and Addiction",
      "category": "behavioral",
      "timeframe": "long_term",
      "severity": "minimal",
      "description": "Potential for dependence on DMT",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "dependencePotential": "Minimal",
          "mechanism": [
            "Classic psychedelics have low abuse potential",
            "Rapid development of tolerance",
            "Self-administration studies in animals generally unsuccessful"
          ],
          "hallucinogenUseDisorder": {
            "lifetimePrevalence": {"value": 0.6, "unit": "percent"},
            "twelveMonthPrevalence": {"value": 0.05, "unit": "percent"},
            "amongUsers": {
              "lifetime": {"value": 6.4, "unit": "percent"},
              "twelveMonth": {"value": 8.1, "unit": "percent"}
            }
          },
          "citations": ["sabe_2024", "ghaznavi_2025"],
          "evidenceQuality": "strong"
        }
      ],
      "clinicalSignificance": "Risk is very low compared to other substances of abuse"
    },
    {
      "id": "ae_dmt_sensitization_001",
      "name": "Sensitization",
      "category": "pharmacological",
      "timeframe": "with_repeated_use",
      "severity": "unclear",
      "description": "Potential sensitization rather than tolerance with repeated DMT use",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "phenomenon": "Repeated administration might lead to sensitization (increased effects) rather than tolerance",
          "note": "More research needed",
          "citations": ["dourron_2023"]
        }
      ],
      "clinicalSignificance": "Unclear; requires further research"
    },
    {
      "id": "ae_dmt_professional_help_001",
      "name": "Need for Professional Mental Health Assistance",
      "category": "composite",
      "timeframe": "post_experience",
      "severity": "variable",
      "description": "Requirement for professional support following adverse DMT experience",
      "substanceOccurrence": [
        {
          "substanceId": "dmt_001",
          "prevalence": {
            "ayahuasca_users": {
              "value": 12,
              "unit": "percent",
              "context": "Reported seeking professional mental health assistance for adverse effects",
              "citations": ["evans_2023", "robinson_2024"]
            }
          }
        }
      ],
      "clinicalSignificance": "Highlights importance of integration support and access to mental health services"
    }
  ],

  "contaminationQualityFactors": [
    {
      "id": "contam_dmt_potency_001",
      "name": "Variability in Potency and Dosing Inaccuracy",
      "category": "quality",
      "severity": "high",
      "description": "Inconsistent DMT concentration and dosing challenges",
      "mechanisms": [
        "Illicit production lacks quality control",
        "Variable purity in recreational sources",
        "Difficult to determine safe dosages",
        "Less consideration of contextual factors in recreational use"
      ],
      "consequences": [
        "Unintended overdoses",
        "Unpredictable effects",
        "Increased risk of adverse reactions"
      ],
      "citations": ["glynos_2023", "gomez-escolar_2024", "bremler_2023", "edwards_2023", "hirschfeld_2021"],
      "evidenceQuality": "strong"
    },
    {
      "id": "contam_dmt_sourcing_001",
      "name": "Unregulated Market Sourcing",
      "category": "sourcing",
      "severity": "high",
      "description": "Risks from obtaining DMT from unregulated sources",
      "specificRisks": [
        {
          "risk": "misrepresentation",
          "description": "Substance may not be what it is purported to be",
          "prevalence": "Common concern",
          "citations": ["glynos_2023", "coyle_nd"]
        },
        {
          "risk": "research_chemicals",
          "description": "Substances sold as 'research chemicals' prone to misrepresentation",
          "contains": "May contain different or unknown compounds",
          "citations": ["coyle_nd"]
        },
        {
          "risk": "cheaper_substitutes",
          "description": "DMT may contain cheaper substitutes with more dangerous side effects",
          "citations": ["petranker_2022"]
        }
      ],
      "harmReduction": [
        "Obtain from trusted sources when possible",
        "Use substance testing services",
        "Start with test doses",
        "Educate about risks"
      ]
    },
    {
      "id": "contam_dmt_adulteration_001",
      "name": "Adulteration and Contaminants",
      "category": "contamination",
      "severity": "high",
      "description": "Presence of adulterants in illicit DMT",
      "commonContaminants": [
        {
          "contaminant": "amphetamines",
          "prevalence": "Documented as trace contaminants",
          "source": "Inadequate cleaning of production equipment or negligent manufacturing",
          "citations": ["aakery_2021"]
        },
        {
          "contaminant": "MDMA",
          "prevalence": "Documented as trace contaminants",
          "source": "Inadequate cleaning of production equipment or negligent manufacturing",
          "citations": ["aakery_2021"]
        }
      ],
      "consequences": [
        "Unpredictable effects",
        "Potentially harmful interactions",
        "Increased toxicity risk",
        "False attribution of effects to DMT"
      ],
      "citations": ["glynos_2023", "aakery_2021", "hirschfeld_2021"],
      "evidenceQuality": "moderate"
    },
    {
      "id": "contam_dmt_testing_001",
      "name": "Lack of Access to Testing",
      "category": "harm_reduction_infrastructure",
      "severity": "high",
      "description": "Limited access to accurate substance testing",
      "barriers": [
        {
          "barrier": "limited_access_to_testing_services",
          "description": "Many users lack access to drug-testing services or kits"
        },
        {
          "barrier": "test_kit_limitations",
          "description": "Available test kits cannot detect all adulterants or accurately measure drug amount"
        },
        {
          "barrier": "lack_of_advanced_analysis",
          "description": "Advanced techniques like LC/GC-MS not readily available to most checking services",
          "techniques": [
            "Liquid chromatography",
            "Gas chromatography",
            "Mass spectrometry"
          ]
        }
      ],
      "consequences": [
        "Users cannot identify potential contaminants",
        "Difficult to determine actual composition",
        "Cannot predict individual response accurately"
      ],
      "citations": ["glynos_2023", "petranker_2022", "hirschfeld_2021"],
      "recommendations": [
        "Increase availability of drug checking services",
        "Educate about test kit use and limitations",
        "Advocate for advanced testing availability",
        "Promote harm reduction testing policies"
      ]
    }
  ],

  "doseResponseCurves": [
    {
      "substanceId": "dmt_001",
      "route": "intravenous",
      "effectMeasure": "somaesthetic_vs_hallucinogenic",
      "relationship": "threshold_effect",
      "dataPoints": [
        {
          "dose": 0.05,
          "unit": "mg/kg",
          "effects": "Mostly somaesthetic effects"
        },
        {
          "dose": 0.1,
          "unit": "mg/kg",
          "effects": "Mostly somaesthetic effects"
        },
        {
          "dose": 0.2,
          "unit": "mg/kg",
          "effects": "Strong hallucinogenic effects present"
        },
        {
          "dose": 0.4,
          "unit": "mg/kg",
          "effects": "Strong hallucinogenic effects"
        }
      ],
      "interpretation": "Clear threshold around 0.2 mg/kg for hallucinogenic effects",
      "citations": ["engel_2024", "strassman_1994"],
      "evidenceQuality": "strong"
    },
    {
      "substanceId": "dmt_001",
      "route": "intravenous",
      "effectMeasure": "mystical_experience_probability",
      "relationship": "dose_dependent",
      "dataPoints": [
        {
          "dose": 0.07,
          "unit": "mg/kg",
          "mysticalExperience": "Rare"
        },
        {
          "dose": 0.14,
          "unit": "mg/kg",
          "mysticalExperience": "Uncommon"
        },
        {
          "dose": 0.29,
          "unit": "mg/kg",
          "mysticalExperience": "More common"
        },
        {
          "dose": 0.43,
          "unit": "mg/kg",
          "mysticalExperience": "Common"
        }
      ],
      "note": "Reliable production of mystical experiences at higher doses",
      "interpretation": "DMT reliably produces mystical experiences at higher dose ranges",
      "citations": ["lancelotta_2020"],
      "evidenceQuality": "moderate"
    },
    {
      "substanceId": "dmt_001",
      "characteristic": "steep_dose_response",
      "description": "DMT has a steep dose-response curve",
      "implications": [
        "Small dose increases can produce large effect increases",
        "Precise dosing critical",
        "Higher risk of accidental overdose with imprecise measuring"
      ],
      "citations": ["lancelotta_2020", "engel_2024"],
      "evidenceQuality": "strong"
    }
  ],

  "complexInteractions": [
    {
      "id": "interact_dmt_maoi_001",
      "factors": [
        {"type": "substance", "id": "dmt_001"},
        {"type": "drug_interaction", "category": "MAOI"},
        {"type": "route", "value": "oral"}
      ],
      "riskMultiplier": "critical",
      "specificOutcome": "Serotonin syndrome - potentially fatal",
      "mechanism": [
        "MAOIs required for oral DMT bioavailability",
        "Excessive serotonin accumulation",
        "Dangerous with concurrent MAOI medications",
        "Risk with tyramine-containing foods"
      ],
      "deathsReported": true,
      "exceptions": [
        "Controlled ayahuasca ceremony with proper protocols",
        "Dietary restrictions (tyramine-free diet)",
        "Medical supervision",
        "Traditional preparation methods"
      ],
      "contraindicationType": "absolute_unless_controlled_protocol",
      "evidenceQuality": "strong",
      "citations": ["malcolm_2022", "dos_santos_2024", "barker_2022"]
    },
    {
      "id": "interact_dmt_mdma_001",
      "factors": [
        {"type": "substance", "id": "dmt_001"},
        {"type": "substance", "name": "MDMA"},
        {"type": "setting", "context": "recreational"}
      ],
      "riskMultiplier": "critical",
      "specificOutcome": "Fatal adverse events documented",
      "mechanism": [
        "Unpredictable pharmacological interaction",
        "Synergistic serotonergic effects",
        "Cardiovascular stress",
        "Hyperthermia risk"
      ],
      "deathsReported": true,
      "contraindicationType": "absolute",
      "evidenceQuality": "strong",
      "citations": ["malcolm_2022", "kopra_2025"]
    },
    {
      "id": "interact_dmt_5meodmt_001",
      "factors": [
        {"type": "substance", "id": "dmt_001"},
        {"type": "substance", "name": "5-MeO-DMT"}
      ],
      "riskMultiplier": "critical",
      "specificOutcome": "Fatal adverse events documented",
      "mechanism": [
        "Combined serotonergic effects",
        "Unpredictable interaction",
        "Possible serotonin syndrome"
      ],
      "deathsReported": true,
      "contraindicationType": "absolute",
      "evidenceQuality": "moderate",
      "citations": ["malcolm_2022", "kopra_2025"]
    },
    {
      "id": "interact_dmt_psychosis_history_001",
      "factors": [
        {"type": "substance", "id": "dmt_001"},
        {"type": "medical_condition", "category": "psychotic_disorders"},
        {"type": "risk_factor", "category": "family_history_psychosis"}
      ],
      "riskMultiplier": "critical",
      "specificOutcome": "Prolonged psychotic reaction or exacerbation",
      "mechanism": [
        "DMT may trigger latent psychotic tendencies",
        "Intense alterations in perception and consciousness",
        "Stress on psychological stability"
      ],
      "contraindicationType": "absolute",
      "evidenceQuality": "strong",
      "citations": ["sabe_2024", "white_2024", "henningfield_2023"]
    },
    {
      "id": "interact_dmt_cardiovascular_rapid_route_001",
      "factors": [
        {"type": "substance", "id": "dmt_001"},
        {"type": "medical_condition", "id": "cond_dmt_cardiovascular_001"},
        {"type": "route", "value": "intravenous_or_smoked"},
        {"type": "risk_factor", "category": "rapid_onset"}
      ],
      "riskMultiplier": "high",
      "specificOutcome": "Acute cardiovascular event",
      "mechanism": [
        "Rapid increase in plasma DMT concentration",
        "Sudden cardiovascular stress",
        "Sympathomimetic effects",
        "Blood pressure and heart rate spikes"
      ],
      "mitigatingFactors": [
        "Slower routes of administration (IM)",
        "Pre-existing cardiovascular stability",
        "Continuous monitoring",
        "Medical supervision"
      ],
      "contraindicationType": "absolute_if_unstable_cardiovascular",
      "evidenceQuality": "moderate",
      "citations": ["barker_2022", "falchi-carvalho_2024"]
    }
  ],

  "emergencyResponseProtocols": [
    {
      "id": "emergency_dmt_nonpharm_001",
      "name": "Non-Pharmacological Interventions for DMT",
      "category": "crisis_management",
      "priority": "first_line",
      "substanceSpecific": "dmt_001",
      "interventions": [
        {
          "intervention": "continuous_monitoring_supervision",
          "description": "Especially critical given DMT's rapid onset and intensity",
          "frequency": "Continuous throughout session",
          "rationale": "Users may lack awareness of behaviors during acute effects",
          "citations": ["dourron_2023", "carbonaro_2016"]
        },
        {
          "intervention": "rapid_reassurance",
          "description": "Quick verbal reassurance given rapid onset of effects",
          "effectiveness": "Sufficient for most anxiety/distress",
          "technique": "Calm, immediate, empathetic response to fast-emerging distress",
          "timing": "Especially important during onset (first 2-5 minutes)"
        },
        {
          "intervention": "physical_safety",
          "description": "Ensure physical safety given risk of involuntary movements",
          "actions": [
            "Soft surfaces",
            "Remove hazards",
            "Prevent falls",
            "Protect from self-injury"
          ],
          "rationale": "DMT can cause involuntary bodily movements and loss of awareness",
          "citations": ["dourron_2023"]
        },
        {
          "intervention": "brief_session_support",
          "description": "Recognize that intense effects are brief (10-60 minutes)",
          "technique": "Remind participant of transient nature given short duration",
          "advantage": "Shorter supervision period than other psychedelics"
        }
      ],
      "effectiveness": "High - manages most cases of distress",
      "citations": ["johnson_2008", "davis_2022"]
    },
    {
      "id": "emergency_dmt_cardiovascular_001",
      "name": "Cardiovascular Monitoring for DMT",
      "category": "physiological_monitoring",
      "priority": "continuous",
      "substanceSpecific": "dmt_001",
      "monitoring": {
        "parameters": [
          "Heart rate",
          "Blood pressure",
          "Oxygen saturation",
          "Body temperature"
        ],
        "frequency": "Real-time continuous monitoring",
        "rationale": "DMT's sympathomimetic effects require cardiovascular vigilance",
        "equipment": [
          "Blood pressure monitor",
          "Pulse oximeter",
          "ECG if available",
          "Thermometer"
        ]
      },
      "thresholds": {
        "heartRate": {
          "concern": ">120 bpm sustained",
          "action": "Increase monitoring frequency, reassurance, consider medical intervention"
        },
        "bloodPressure": {
          "concern": "Systolic >160 or Diastolic >100",
          "action": "Medical assessment, potential pharmacological intervention"
        },
        "bradycardia": {
          "note": "Rare asymptomatic bradycardia documented",
          "action": "Monitor but usually benign"
        }
      },
      "citations": ["falchi-carvalho_2024", "ramaekers_2025", "luan_2024", "white_2024"]
    },
    {
      "id": "emergency_dmt_behavioral_001",
      "name": "Managing DMT Behavioral Manifestations",
      "category": "behavioral_crisis",
      "priority": "immediate",
      "substanceSpecific": "dmt_001",
      "challenges": [
        {
          "challenge": "loss_of_awareness",
          "description": "User may not be aware of their actions",
          "response": [
            "Do not leave user unattended",
            "Gentle physical guidance if needed",
            "Protect from hazards",
            "Prevent dangerous actions"
          ]
        },
        {
          "challenge": "odd_vocalizations",
          "description": "Unusual sounds or screaming",
          "response": [
            "Remain calm",
            "Reassure other people present",
            "Do not restrain unless necessary for safety",
            "Recognize as transient effect"
          ]
        },
        {
          "challenge": "removing_clothes",
          "description": "User may remove clothing",
          "response": [
            "Gentle redirection",
            "Protect dignity and privacy",
            "Ensure appropriate room temperature",
            "Do not force unless safety concern"
          ]
        },
        {
          "challenge": "self_injurious_behavior",
          "description": "Rare but potential for self-harm",
          "response": [
            "Immediate intervention",
            "Gentle physical restraint if necessary",
            "Remove sharp objects preemptively",
            "Medical assessment after",
            "Psychiatric follow-up"
          ]
        }
      ],
      "preparation": [
        "Clear room of hazards before session",
        "Have two facilitators present if possible",
        "Discuss behavioral boundaries in preparation",
        "Have plan for physical safety"
      ],
      "citations": ["dourron_2023"]
    },
    {
      "id": "emergency_dmt_route_specific_001",
      "name": "Route-Specific Emergency Considerations",
      "category": "route_dependent",
      "substanceSpecific": "dmt_001",
      "routes": [
        {
          "route": "inhalation",
          "emergencies": [
            {
              "emergency": "respiratory_distress",
              "response": [
                "Fresh air",
                "Sitting position",
                "Reassurance",
                "Oxygen if available",
                "Medical assessment if severe"
              ]
            },
            {
              "emergency": "coughing_fit",
              "response": [
                "Water available",
                "Calm breathing guidance",
                "Usually self-limiting"
              ]
            }
          ]
        },
        {
          "route": "intravenous",
          "emergencies": [
            {
              "emergency": "rapid_intense_reaction",
              "response": [
                "Medical personnel must be present",
                "Continuous monitoring",
                "Benzodiazepines readily available",
                "Emergency equipment on hand"
              ]
            },
            {
              "emergency": "cardiovascular_crisis",
              "response": [
                "Immediate medical intervention",
                "Antihypertensives if needed",
                "Transfer to emergency care if necessary"
              ]
            }
          ]
        },
        {
          "route": "oral_with_MAOI",
          "emergencies": [
            {
              "emergency": "serotonin_syndrome",
              "response": [
                "Recognize symptoms: hyperthermia, muscle rigidity, altered mental status",
                "Discontinue all serotonergic agents",
                "Immediate medical transport",
                "Cooling measures",
                "Benzodiazepines",
                "ICU level care may be needed"
              ]
            },
            {
              "emergency": "hypertensive_crisis",
              "response": [
                "From tyramine interaction",
                "Immediate blood pressure management",
                "Emergency medical services",
                "Antihypertensive medication"
              ]
            },
            {
              "emergency": "prolonged_effects",
              "response": [
                "Recognize longer duration with ayahuasca",
                "Extended supervision required",
                "May need 4-6 hour monitoring period"
              ]
            }
          ]
        }
      ]
    }
  ],

  "preparationPractices": [
    {
      "id": "prep_dmt_specific_education_001",
      "name": "DMT-Specific Psychoeducation",
      "category": "education",
      "timing": "pre_session",
      "substanceSpecific": "dmt_001",
      "content": [
        {
          "topic": "unique_phenomenology",
          "details": [
            "Extremely rapid onset (especially inhaled/IV)",
            "Very intense but brief experience",
            "Potential for 'breakthrough' experiences",
            "Entity encounters common",
            "Sense of alternate dimensions/realities",
            "Complete ego dissolution possible",
            "Differs significantly from other psychedelics"
          ]
        },
        {
          "topic": "route_specific_effects",
          "details": [
            "Inhalation: seconds onset, 10-60 min duration",
            "IV: immediate onset, 10-30 min duration",
            "Oral with MAOI: slower onset, 4-6 hour duration",
            "IM: slightly slower than IV",
            "Different routes produce different experience profiles"
          ]
        },
        {
          "topic": "behavioral_effects",
          "details": [
            "May lack awareness during peak",
            "Possible unusual vocalizations",
            "Muscle jerking/twitching possible",
            "Loss of behavioral control briefly",
            "Importance of supervision"
          ]
        },
        {
          "topic": "reactivations_flashbacks",
          "details": [
            "Brief re-experiences possible days/weeks later",
            "More common with DMT than other psychedelics",
            "Usually positive or neutral",
            "Brief (seconds) in duration",
            "May occur more at night",
            "Usually not distressing"
          ]
        },
        {
          "topic": "ayahuasca_specific",
          "details": [
            "Requires MAOI for oral activity",
            "Longer duration (4-6 hours)",
            "Purging (vomiting) common and culturally significant",
            "Dietary restrictions essential",
            "Medication interactions critical to review"
          ]
        }
      ],
      "effectiveness": "high",
      "citations": ["white_2024", "dourron_2023", "ramaekers_2025"]
    },
    {
      "id": "prep_dmt_rapid_onset_001",
      "name": "Preparation for Rapid Onset",
      "category": "psychological",
      "timing": "pre_session",
      "substanceSpecific": "dmt_001",
      "uniqueChallenge": "Extremely rapid onset leaves little time for psychological adjustment during experience",
      "strategies": [
        {
          "strategy": "mental_preparation_immediacy",
          "description": "Prepare for immediate onset with inhalation/IV routes",
          "techniques": [
            "Practice surrender before administration",
            "Be mentally ready before dose",
            "No opportunity to 'ease into' experience",
            "Commit to the experience fully beforehand"
          ]
        },
        {
          "strategy": "breathing_pre_administration",
          "description": "Practice calming breath before administration",
          "rationale": "Establish calm state as baseline before rapid onset",
          "timing": "5-10 minutes before administration"
        },
        {
          "strategy": "body_position",
          "description": "Optimal positioning before administration",
          "recommendation": "Lying down or well-supported sitting position",
          "rationale": "No time to adjust position once effects begin",
          "safety": "Prevents falls during rapid onset"
        },
        {
          "strategy": "environment_ready",
          "description": "Ensure environment completely prepared before administration",
          "checklist": [
            "All hazards removed",
            "Comfortable temperature",
            "Music/silence preference set",
            "Eyeshades ready if desired",
            "Facilitator positioned",
            "No planned interruptions"
          ]
        }
      ],
      "citations": ["fradkin_2024", "white_2024", "james_2024"]
    },
    {
      "id": "prep_dmt_route_selection_001",
      "name": "Route Selection Counseling",
      "category": "practical",
      "timing": "pre_session",
      "substanceSpecific": "dmt_001",
      "importance": "Critical given different risk profiles of routes",
      "considerations": [
        {
          "factor": "experience_level",
          "guidance": [
            "First-time users: Consider slower routes (IM) or very low inhaled dose",
            "Experienced users: May choose based on desired intensity/duration",
            "Never IV for first-time psychedelic users"
          ]
        },
        {
          "factor": "medical_considerations",
          "guidance": [
            "Cardiovascular concerns: Avoid IV/inhaled routes",
            "Respiratory issues: Avoid inhalation",
            "Taking MAOIs or SSRIs: Avoid oral DMT with MAOI",
            "Epilepsy: Avoid all routes"
          ]
        },
        {
          "factor": "therapeutic_goals",
          "guidance": [
            "Brief insight-oriented: Inhalation may be suitable",
            "Deep psychological work: IM or ayahuasca ceremony",
            "Research setting: Usually IV for control",
            "Spiritual/ceremonial: Traditional ayahuasca"
          ]
        },
        {
          "factor": "practical_considerations",
          "guidance": [
            "Time available: Inhalation/IV if limited time",
            "Supervision availability: Extended for ayahuasca",
            "Legal context: Ayahuasca churches in some jurisdictions",
            "Cultural context: Respect traditional ayahuasca use"
          ]
        }
      ]
    },
    {
      "id": "prep_dmt_medication_review_001",
      "name": "Comprehensive Medication Review",
      "category": "safety_screening",
      "timing": "pre_session",
      "substanceSpecific": "dmt_001",
      "criticality": "Essential, especially for ayahuasca",
      "screening": [
        {
          "category": "MAOIs",
          "medications": [
            "Phenelzine",
            "Tranylcypromine",
            "Isocarboxazid",
            "Selegiline (at higher doses)"
          ],
          "contraindicationType": "absolute_unless_controlled_ayahuasca",
          "washoutPeriod": "Minimum 2 weeks"
        },
        {
          "category": "SSRIs_SNRIs",
          "medications": [
            "Fluoxetine",
            "Sertraline",
            "Paroxetine",
            "Citalopram",
            "Venlafaxine",
            "Duloxetine"
          ],
          "risk": "Serotonin syndrome especially with MAOI-containing preparations",
          "contraindicationType": "relative_to_absolute",
          "washoutPeriod": "Variable by medication; fluoxetine 4-6 weeks"
        },
        {
          "category": "other_serotonergic",
          "medications": [
            "Triptans (migraine medications)",
            "Tramadol",
            "Certain cough medications (dextromethorphan)",
            "St. John's Wort"
          ],
          "risk": "Serotonin syndrome",
          "recommendation": "Discontinue with appropriate washout"
        },
        {
          "category": "cardiovascular_medications",
          "assessment": "Review for interactions and assess cardiovascular stability"
        }
      ],
      "ayahuascaSpecific": {
        "dietaryRestrictions": [
          "Tyramine-free diet essential",
          "Avoid: aged cheeses, cured meats, fermented foods, alcohol",
          "Typically 1-2 days before and after",
          "Risk of hypertensive crisis with tyramine + MAOI"
        ]
      },
      "citations": ["dos_santos_2024", "malcolm_2022", "barker_2022"]
    }
  ],

  "integrationPractices": [
    {
      "id": "int_dmt_rapid_integration_001",
      "name": "Rapid-Onset Integration",
      "category": "therapeutic",
      "timing": "immediate_post_session",
      "substanceSpecific": "dmt_001",
      "uniqueAspect": "Very brief but extremely intense experience requires immediate processing",
      "structure": {
        "immediate": {
          "timing": "Within minutes to hours post-session",
          "rationale": "Experience fresh in memory but may fade quickly",
          "activities": [
            "Verbal processing while memory vivid",
            "Initial journaling or recording",
            "Discussing with facilitator while present",
            "Capturing ineffable elements before they fade"
          ]
        },
        "same_day": {
          "timing": "Later same day",
          "activities": [
            "More structured reflection",
            "Artistic expression",
            "Written narrative",
            "Discussion with facilitator or integration therapist"
          ]
        },
        "ongoing": {
          "timing": "Days to weeks",
          "activities": [
            "Standard integration practices",
            "Processing entity encounters if occurred",
            "Making meaning of breakthrough experiences",
            "Addressing any flashbacks/reactivations"
          ]
        }
      },
      "citations": ["bathje_2022", "garcia-romeu_2018"]
    },
    {
      "id": "int_dmt_ineffability_001",
      "name": "Addressing Ineffability",
      "category": "meaning_making",
      "timing": "post_session",
      "substanceSpecific": "dmt_001",
      "challenge": "DMT experiences often described as uniquely difficult to verbalize",
      "approaches": [
        {
          "approach": "multiple_modalities",
          "description": "Use various forms of expression",
          "modalities": [
            "Verbal description",
            "Visual art",
            "Music",
            "Movement/dance",
            "Poetry",
            "Metaphor"
          ],
          "rationale": "No single modality may capture experience"
        },
        {
          "approach": "gradual_articulation",
          "description": "Allow understanding to emerge over time",
          "process": [
            "Initial raw impressions",
            "Gradual refinement of description",
            "Emergence of personal meaning",
            "Integration of insights"
          ]
        },
        {
          "approach": "shared_language",
          "description": "Connect with others who have had DMT experiences",
          "benefit": "Common vocabulary and understanding",
          "caution": "Avoid adopting others' interpretations wholesale"
        },
        {
          "approach": "acceptance_of_mystery",
          "description": "Allow some aspects to remain mysterious",
          "wisdom": "Not everything needs to be fully articulated",
          "focus": "What can be integrated and applied"
        }
      ]
    },
    {
      "id": "int_dmt_entity_encounters_001",
      "name": "Processing Entity Encounters",
      "category": "phenomenological",
      "timing": "post_session",
      "substanceSpecific": "dmt_001",
      "uniqueAspect": "Entity encounters particularly common with DMT",
      "approaches": [
        {
          "approach": "open_exploration",
          "description": "Explore without imposing interpretations",
          "questions": [
            "What was the quality of the encounter?",
            "What emotions did it evoke?",
            "Was there communication? What was conveyed?",
            "How did the entity appear?",
            "What personal meaning does it hold?"
          ]
        },
        {
          "approach": "multiple_frameworks",
          "description": "Consider various interpretive frameworks",
          "frameworks": [
            "Psychological (projections, archetypes)",
            "Neurological (brain activity patterns)",
            "Spiritual (actual beings or dimensions)",
            "Agnostic (phenomenological description without ontological claims)"
          ],
          "guidance": "Support individual's framework while acknowledging uncertainty"
        },
        {
          "approach": "personal_meaning",
          "description": "Focus on personal significance",
          "emphasis": "What matters is not 'what it was' but 'what it means to you'"
        },
        {
          "approach": "avoid_spiritual_bypassing",
          "description": "Ensure experience is genuinely processed",
          "caution": "Don't use 'spiritual' interpretation to avoid psychological work"
        }
      ],
      "citations": ["luan_2024", "fradkin_2024"]
    },
    {
      "id": "int_dmt_reactivations_001",
      "name": "Managing Reactivations/Flashbacks",
      "category": "symptom_management",
      "timing": "post_session_ongoing",
      "substanceSpecific": "dmt_001",
      "prevalence": "More common with DMT than other psychedelics",
      "integration": [
        {
          "aspect": "normalization",
          "description": "Educate that reactivations are common and usually benign",
          "reassurance": "Most are brief, positive or neutral, and decrease over time"
        },
        {
          "aspect": "tracking",
          "description": "Encourage keeping log of reactivations",
          "tracking": [
            "Frequency",
            "Duration",
            "Content",
            "Context (time of day, activity)",
            "Emotional valence"
          ],
          "benefit": "Identify patterns, monitor decrease over time"
        },
        {
          "aspect": "non_reactivity",
          "description": "Practice observing without alarming",
          "technique": "Mindful awareness, noting reactivation without resistance",
          "rationale": "Resistance may increase distress"
        },
        {
          "aspect": "when_to_seek_help",
          "description": "Indicators that professional support needed",
          "red_flags": [
            "Increasing frequency over time",
            "Causing significant distress",
            "Interfering with daily functioning",
            "Accompanied by other concerning symptoms"
          ]
        },
        {
          "aspect": "positive_reframe",
          "description": "For positive reactivations, can be seen as reminders",
          "perspective": "Brief reconnection with insights from experience"
        }
      ],
      "citations": ["dourron_2023", "ortiz_bernal_2022", "ramaekers_2025"]
    },
    {
      "id": "int_dmt_ayahuasca_specific_001",
      "name": "Ayahuasca-Specific Integration",
      "category": "ceremonial_context",
      "timing": "post_ceremony",
      "substanceSpecific": "oral_dmt_with_maoi",
      "culturalContext": "Respect traditional integration practices",
      "components": [
        {
          "component": "community_integration",
          "description": "Integration within ceremony community if applicable",
          "practices": [
            "Sharing circles",
            "Group integration sessions",
            "Ongoing community connection"
          ]
        },
        {
          "component": "dietary_continuation",
          "description": "Some traditions recommend dietary practices post-ceremony",
          "duration": "Variable (days to weeks)",
          "purpose": "Support integration, maintain 'dieta' practice"
        },
        {
          "component": "somatic_integration",
          "description": "Body-based integration particularly important for ayahuasca",
          "practices": [
            "Yoga",
            "Breathwork",
            "Dance/movement",
            "Somatic psychotherapy"
          ],
          "rationale": "Purging and physical aspects of experience require body-based processing",
          "citations": ["cowley-court_2023"]
        },
        {
          "component": "cultural_respect",
          "description": "Honor indigenous traditions",
          "considerations": [
            "Acknowledge source of practice",
            "Respect ceremonial context",
            "Avoid appropriation",
            "Support source communities when possible"
          ]
        },
        {
          "component": "extended_duration",
          "description": "Longer experience requires extended processing",
          "note": "4-6 hour journey provides more material to integrate than brief DMT experience"
        }
      ],
      "citations": ["bathje_2022", "cowley-court_2023"]
    }
  ],

  "metadata": {
    "documentSource": "DMT Literature Review - Psychedelic Safety Institute",
    "substanceFocus": "N,N-Dimethyltryptamine (DMT)",
    "totalSections": "Comprehensive coverage",
    "primaryResearchTypes": [
      "clinical_trials",
      "case_reports",
      "observational_studies",
      "literature_reviews",
      "traditional_use_documentation"
    ],
    "geographicScope": "Global, with emphasis on clinical research settings and Amazonian traditional use",
    "lastLiteratureSearch": "2024-2025",
    "qualityAssessment": "Variable - strong clinical data, limited long-term follow-up, emerging research area",
    "knownLimitations": [
      "Limited large-scale clinical trials compared to psilocybin/LSD",
      "Underreporting of adverse events likely in recreational contexts",
      "Limited diversity in research populations",
      "Few long-term follow-up studies",
      "Ayahuasca research complicated by multiple active compounds",
      "Entity encounter phenomenology difficult to study systematically",
      "Route-specific effects not fully characterized",
      "Reactivation/flashback mechanism poorly understood",
      "Optimal integration protocols still being developed"
    ],
    "uniqueAspectsOfDMT": [
      "Extremely brief duration compared to other psychedelics",
      "Very rapid onset especially with inhalation/IV routes",
      "Reliably produces 'breakthrough' experiences at higher doses",
      "Entity encounters particularly characteristic",
      "Higher prevalence of reactivations than other psychedelics",
      "Requires MAOI for oral bioavailability",
      "Traditional use in ayahuasca ceremonies",
      "Potential for sensitization rather than tolerance",
      "May be more scalable therapeutically due to short duration",
      "Steep dose-response curve"
    ],
    "emergingResearchAreas": [
      "Extended-state DMT (continuous infusion)",
      "Therapeutic applications for depression",
      "Neurobiological mechanisms of entity encounters",
      "Intranasal DMT formulations",
      "Optimal integration protocols",
      "Long-term cognitive effects",
      "Reactivation mechanisms",
      "Comparative studies with other psychedelics"
    ],
    "citations_note": "All citations referenced throughout are from the source literature review document"
  }
}